Retrotope willl make a presentation entitled:
RT001 First-in Human Clinical Trial Demonstrates Safety, Favorable Pharmacokinetics, and Early Signals of Efficacy in Friedreich’s Ataxia
Retrotope will make a poster presentation entitled:
Isotope-Reinforced Polyunsaturated Lipids (D-PUFA) Mitigate Symptoms in Diverse Alzheimer’s Mouse Models
Founder and Chief Scientist Misha Shchepinov will present:
PUFAs are essential nutrients vital for biological, particularly mitochondrial and neuronal, membranes. Unlike any other type of oxidative stress-related damage, lipid peroxidation is a chain process which, once initiated, can damage thousands of PUFA residues before the reaction is terminated. The rate limiting step of the process is hydrogen abstraction at the bis-allylic (between double bonds) site. Antioxidants are inefficient for various reasons. A novel approach employs deuteration of PUFAs at the bis-allylic positions to stops lipid peroxidation by inhibiting the rate limiting step (hydrogen abstraction) due to the isotope effect. Numerous cell culture and animal studies, as well as Phase I in humans, support the role of LPO in neurological and other diseases, and offer a novel therapeutical intervention.
Retrotope will be a presenter at this Symposium.
"Join USF Ataxia Research Center leadership, Dr. Theresa Zesiewicz MD., FAAN, along with FARA Executive Director, Jennifer Farmer and President, Ronald Bartek for a special interactive symposium focused on advancing therapeutic approaches. The symposium will feature updates for ongoing clinical trials along with drug discovery efforts targeting the root cause of this genetic disease. Top researchers will share insights into emerging treatments for Friedreich’s Ataxia. A special panel of individuals living with FA will also share their experiences and perspectives."
Retrotope CSO Misha Shchepinov will present a paper titled
"Lipid Peroxidation-Resistant Polyunsaturated Fatty Acids (PUFA)"
at the "Non-enzymatic lipid oxidation" session which is scheduled for
Wednesday, Sept. 7th.
Poster session presentation by Dr. Robert LeMoyne on "Wearable Body and Wireless Inertial Sensors for Machine Learning Classification of Gait for People with Friedreich’s Ataxia"
Authors: Robert LeMoyne, Frederic Heerinckx, Tanya Aranca, Robert De Jager, Theresa Zesiewicz, Harry J. Saal
Retrotope, Inc., an emerging, clinical stage degenerative disease therapeutic company, gave a presentation at the International Ataxia Research Conference. The talk entitled: “An upcoming clinical trial testing the safety and efficacy of a stabilized polyunsaturated fatty acid in Friedreich’s ataxia” elucidated the company’s progress towards an Investigational New Drug (IND) application for the fatal, orphan disease, Friedreich’s ataxia (FRDA). Currently, there is no approved therapy for FRDA. See the News section for further details.
Isotopes in Biological & Chemical Sciences
February 2-7, 2014
Retrotope is to present at the Gordon Research Conference "Isotopes in Biological and Chemical Sciences" in Galveston, TX. http://www.grc.org/programs.aspx?year=2014&program=isotopes
For more information please contact Retrotope at email@example.com.